Morishita Jintan Co., Ltd. (TYO:4524)
Japan
· Delayed Price · Currency is JPY 2,316.00
-12.00 (-0.52%)
Mar 10, 2026, 10:10 AM JST
Morishita Jintan Revenue
Morishita Jintan had revenue of 3.19B JPY in the quarter ending December 31, 2025, a decrease of -0.75%. This brings the company's revenue in the last twelve months to 12.87B, up 1.86% year-over-year. In the fiscal year ending March 31, 2025, Morishita Jintan had annual revenue of 12.77B with 2.90% growth.
Revenue (ttm)
12.87B
Revenue Growth
+1.86%
P/S Ratio
0.74
Revenue / Employee
36.16M
Employees
356
Market Cap
9.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12.77B | 360.00M | 2.90% |
| Mar 31, 2024 | 12.41B | 1.05B | 9.22% |
| Mar 31, 2023 | 11.36B | 1.80B | 18.78% |
| Mar 31, 2022 | 9.56B | 134.00M | 1.42% |
| Mar 31, 2021 | 9.43B | -345.00M | -3.53% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Solasia Pharma K.K. | 429.00M |
| SymBio Pharmaceuticals | 1.31B |
| Wakamoto Pharmaceutical | 9.43B |
| WDB coco | 4.98B |
| Nippon Chemiphar | 32.52B |
| Cyfuse Biomedical K.K. | 230.00M |
| MedRx | 128.00M |
| Taiko Pharmaceutical | 6.40B |